Signaturefd LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,475 shares of the medical research company’s stock after buying an additional 128 shares during the quarter. Signaturefd LLC’s holdings in Thermo Fisher Scientific were worth $4,687,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. Arjuna Capital grew its stake in Thermo Fisher Scientific by 17.4% during the 2nd quarter. Arjuna Capital now owns 16,617 shares of the medical research company’s stock worth $9,189,000 after purchasing an additional 2,457 shares in the last quarter. Stephens Consulting LLC grew its stake in Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. WestEnd Advisors LLC grew its stake in Thermo Fisher Scientific by 11.9% during the 2nd quarter. WestEnd Advisors LLC now owns 70,253 shares of the medical research company’s stock worth $38,850,000 after purchasing an additional 7,468 shares in the last quarter. Smith Salley Wealth Management lifted its holdings in Thermo Fisher Scientific by 5.7% during the 2nd quarter. Smith Salley Wealth Management now owns 41,583 shares of the medical research company’s stock worth $22,995,000 after buying an additional 2,240 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Thermo Fisher Scientific by 31.9% during the 2nd quarter. Principal Financial Group Inc. now owns 1,022,270 shares of the medical research company’s stock worth $565,316,000 after buying an additional 247,110 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Thermo Fisher Scientific
In related news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares of the company’s stock, valued at approximately $8,397,760.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at $8,397,760.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. The disclosure for this sale can be found here. Insiders sold 33,084 shares of company stock valued at $19,767,092 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same period last year, the business posted $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was down 1.4% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Wells Fargo & Company initiated coverage on Thermo Fisher Scientific in a report on Tuesday. They issued an “overweight” rating and a $670.00 target price for the company. Finally, Royal Bank of Canada boosted their target price on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $630.41.
Check Out Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Consumer Discretionary Stocks Explained
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What is the Dow Jones Industrial Average (DJIA)?
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.